{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:02:52Z","timestamp":1779933772999,"version":"3.53.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Province Medical and Health Research Projects","award":["2016KYB027"],"award-info":[{"award-number":["2016KYB027"]}]},{"name":"Zhejiang Province Medical and Health Research Projects","award":["2017KY010"],"award-info":[{"award-number":["2017KY010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08119-9","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:46:30Z","timestamp":1776257190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular and clinical characteristics of glioma patients with germline pathogenic mutations of Lynch syndrome genes: a large-scale multicenter study"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiao","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonghui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guhong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiyuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengchuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaiyuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"8119_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc3878","volume":"15","author":"HT Lynch","year":"2015","unstructured":"Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895\u20132015. Nat Rev Cancer. 2015;15:181\u201394.","journal-title":"Nat Rev Cancer"},{"key":"8119_CR2","unstructured":"Peltom\u00e4ki P. Reference Module in Biomedical Sciences. United Kingdom: Elsevier; 2017."},{"key":"8119_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJMcp1714533","volume":"379","author":"FA Sinicrope","year":"2018","unstructured":"Sinicrope FA. Lynch Syndrome\u2013Associated Colorectal Cancer. N Engl J Med. 2018;379:764\u201373.","journal-title":"N Engl J Med"},{"key":"8119_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev-genom-083118-015406","volume":"20","author":"SA Cohen","year":"2019","unstructured":"Cohen SA, Pritchard CC, Jarvik GP. Lynch Syndrome: From Screening to Diagnosis to Treatment in the Era of Modern Molecular Oncology. Annu Rev Genom Hum Genet. 2019;20:293\u2013307.","journal-title":"Annu Rev Genom Hum Genet"},{"key":"8119_CR5","unstructured":"Idos G, Valle L. GeneReviews(\u00ae). Seattle, Seattle (WA): University of Washington; 1993."},{"key":"8119_CR6","first-page":"1872","volume":"23","author":"Y Yu","year":"2021","unstructured":"Yu Y, et al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neurooncology. 2021;23:1872\u201384.","journal-title":"Neurooncology"},{"key":"8119_CR7","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"key":"8119_CR8","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet E, et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol. 2016;34:2206\u201311.","journal-title":"J Clin Oncol"},{"key":"8119_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2159-8290.CD-23-0559","volume":"14","author":"AA-O Das","year":"2024","unstructured":"Das AA-O, et al. Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium. Cancer Discov. 2024;14:258\u201373.","journal-title":"Cancer Discov"},{"key":"8119_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00401-023-02654-1","volume":"147","author":"S Hadad","year":"2023","unstructured":"Hadad S, et al. \"De novo replication repair deficient glioblastoma, IDH-wildtype\" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. Acta Neuropathol. 2023;147:3.","journal-title":"Acta Neuropathol"},{"key":"8119_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1470-2045(24)00640-5","volume":"26","author":"L Negm","year":"2025","unstructured":"Negm L, et al. The landscape of primary mismatch repair deficient gliomas in children, adolescents, and young adults: a multi-cohort study. Lancet Oncol. 2025;26:123\u201335.","journal-title":"Lancet Oncol"},{"key":"8119_CR12","first-page":"1231","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neurooncology. 2021;23:1231\u201351.","journal-title":"Neurooncology"},{"key":"8119_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1200\/JCO.18.00283","volume":"37","author":"A Latham","year":"2019","unstructured":"Latham A, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol. 2019;37:286\u201395.","journal-title":"J Clin Oncol"},{"key":"8119_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","volume":"580","author":"M Touat","year":"2020","unstructured":"Touat M, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020;580:517\u201323.","journal-title":"Nature"},{"key":"8119_CR15","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-06-0127","volume":"66","author":"C Hunter","year":"2006","unstructured":"Hunter C, et al. A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy. Cancer Res. 2006;66:3987\u201391.","journal-title":"Cancer Res"},{"key":"8119_CR16","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-06-2149","volume":"13","author":"DP Cahill","year":"2007","unstructured":"Cahill DP, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007;13:2038\u201345.","journal-title":"Clin Cancer Res"},{"key":"8119_CR17","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","volume":"15","author":"S Yip","year":"2009","unstructured":"Yip S, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009;15:4622\u20139.","journal-title":"Clin Cancer Res"},{"key":"8119_CR18","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1158\/1078-0432.CCR-07-4807","volume":"14","author":"JA Maxwell","year":"2008","unstructured":"Maxwell JA, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res. 2008;14:4859\u201368.","journal-title":"Clin Cancer Res"},{"key":"8119_CR19","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114\u201320.","journal-title":"Bioinformatics"},{"key":"8119_CR20","unstructured":"Heng L. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv. (2013)."},{"key":"8119_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo MA, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491\u20138.","journal-title":"Nat Genet"},{"key":"8119_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213\u20139.","journal-title":"Nat Biotechnol"},{"key":"8119_CR23","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders CT, et al. Strelka: accurate somatic small-variant calling from sequenced tumor\u2013normal sample pairs. Bioinformatics. 2012;28:1811\u20137.","journal-title":"Bioinformatics"},{"key":"8119_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122.","journal-title":"Genome Biol"},{"key":"8119_CR25","doi-asserted-by":"publisher","first-page":"E2423","DOI":"10.1002\/humu.22771","volume":"36","author":"AH Ramos","year":"2015","unstructured":"Ramos AH, et al. Oncotator: Cancer Variant Annotation Tool. Hum Mutat. 2015;36:E2423\u20139.","journal-title":"Hum Mutat"},{"key":"8119_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/bib\/bbs017","volume":"14","author":"H Thorvaldsd\u00f3ttir","year":"2012","unstructured":"Thorvaldsd\u00f3ttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2012;14:178\u201392.","journal-title":"Brief Bioinform"},{"key":"8119_CR27","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/1471-2164-15-732","volume":"15","author":"KC Amarasinghe","year":"2014","unstructured":"Amarasinghe KC, et al. Inferring copy number and genotype in tumour exome data. BMC Genomics. 2014;15:732.","journal-title":"BMC Genomics"},{"key":"8119_CR28","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nmeth.1628","volume":"8","author":"J Wang","year":"2011","unstructured":"Wang J, et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods. 2011;8:652\u20134.","journal-title":"Nat Methods"},{"key":"8119_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703\u201313.","journal-title":"Nat Med"},{"key":"8119_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.","journal-title":"Genome Med"},{"key":"8119_CR31","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1053\/gast.2002.37070","volume":"123","author":"N Suraweera","year":"2002","unstructured":"Suraweera N, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002;123:1804\u201311.","journal-title":"Gastroenterology"},{"key":"8119_CR32","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/bjc.2017.348","volume":"117","author":"C Therkildsen","year":"2017","unstructured":"Therkildsen C, Ladelund S, Smith-Hansen L, Lindberg LJ, Nilbert M. Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types. Br J Cancer. 2017;117:1702\u201310.","journal-title":"Br J Cancer"},{"key":"8119_CR33","first-page":"1300","volume":"20","author":"S Choi","year":"2018","unstructured":"Choi S, et al. Temozolomide-associated hypermutation in gliomas. Neurooncology. 2018;20:1300\u20139.","journal-title":"Neurooncology"},{"key":"8119_CR34","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert MR, et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. J Clin Oncol. 2013;31:4085\u201391.","journal-title":"J Clin Oncol"},{"key":"8119_CR35","first-page":"571","volume":"8","author":"SD Ramsey","year":"2006","unstructured":"Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. Population-based study of the prevalence of family history of cancer: Implications for cancer screening and prevention. Genet Sci. 2006;8:571\u20135.","journal-title":"Genet Sci"},{"key":"8119_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/neuonc\/noaa227","volume":"23","author":"I Alnahhas","year":"2021","unstructured":"Alnahhas I, Rayi A, Ong S, Giglio P, Puduvalli V. Management of gliomas in patients with Lynch syndrome. Neuro Oncol. 2021;23:167\u20138.","journal-title":"Neuro Oncol"},{"key":"8119_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/1066527041410418","volume":"11","author":"Maximum Entropy Modeling of Short Sequence","year":"2004","unstructured":"Maximum Entropy Modeling of Short Sequence. Motifs with Applications to RNA Splicing Signals. J Comput Biol. 2004;11:377\u201394.","journal-title":"J Comput Biol"},{"key":"8119_CR38","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/nar\/24.17.3439","volume":"24","author":"SM Hebsgaard","year":"1996","unstructured":"Hebsgaard SM, et al. Splice Site Prediction in Arabidopsis Thaliana Pre-mRNA by Combining Local and Global Sequence Information. Nucleic Acids Res. 1996;24:3439\u201352.","journal-title":"Nucleic Acids Res"},{"key":"8119_CR39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.gene.2005.07.015","volume":"366","author":"M Wang","year":"2006","unstructured":"Wang M, Mar\u00edn A. Characterization and prediction of alternative splice sites. Gene. 2006;366:219\u201327.","journal-title":"Gene"},{"key":"8119_CR40","first-page":"1105","volume":"19","author":"K Nykamp","year":"2017","unstructured":"Nykamp K, et al. Sherloc: a comprehensive refinement of the ACMG\u2013AMP variant classification criteria. Genet Sci. 2017;19:1105\u201317.","journal-title":"Genet Sci"},{"key":"8119_CR41","doi-asserted-by":"crossref","unstructured":"Dominguez-Valentin M et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2020;22(1):15\u201325.","DOI":"10.1038\/s41436-019-0716-6"},{"key":"8119_CR42","doi-asserted-by":"crossref","unstructured":"Benusiglio PR et al. Mismatch repair deficiency and lynch syndrome among adult patients with Glioma. 2023;7:e2200525.","DOI":"10.1200\/PO.22.00525"},{"key":"8119_CR43","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nrneurol.2014.100","volume":"10","author":"W Wick","year":"2014","unstructured":"Wick W, et al. MGMT testing\u2014the challenges for biomarker-based glioma treatment. Nat Reviews Neurol. 2014;10:372\u201385.","journal-title":"Nat Reviews Neurol"},{"key":"8119_CR44","doi-asserted-by":"crossref","unstructured":"Latham A et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol. 2019;37(4):286\u201395.","DOI":"10.1200\/JCO.18.00283"},{"key":"8119_CR45","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17:e542\u201351.","journal-title":"Lancet Oncol"},{"key":"8119_CR46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15:422\u201342.","journal-title":"Nat Rev Clin Oncol"},{"key":"8119_CR47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3:198\u2013210.","journal-title":"Genes Dis"},{"key":"8119_CR48","first-page":"17","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021;4:17\u201343.","journal-title":"Cancer Drug Resist"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08119-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:03:06Z","timestamp":1779930186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08119-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8119"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08119-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tonghui Ma is employed by Genecn-Biotech Co., Ltd. and Genetron Health (Beijing) Co., Ltd. Xiang Zhang, Wei Li, Xiaomo Li, and Yanxiang Zhang are employed by Genetron Health (Beijing) Co., Ltd. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"711"}}